is sports betting legal in california
is sports betting legal in california
Stock market today: Wall Street gets back to climbing, and the Nasdaq tops 20,000
NEW YORK--(BUSINESS WIRE)--Dec 4, 2024-- Uniswap Labs, the leader in decentralized finance (DeFi), is making it easier for institutional firms to access DeFi through its collaboration with Fireblocks, a digital asset operations and payments platform trusted by 2,000 clients globally. Through Fireblocks, asset managers, hedge funds, and other financial firms can access Uniswap Protocol’s liquidity and advanced DeFi trading features. “We’re thrilled to bring DeFi native capabilities that meet our clients' demand for secure, scalable access to deeper liquidity,” said Michael Shaulov, CEO of Fireblocks. “We see increasing appetite for DeFi solutions among financial institutions, and we’re excited to see more of our clients diversify their digital assets portfolio with Uniswap’s Trading API.” Direct to DeFi The Uniswap Trading API is developed and maintained by Uniswap Labs, the US-based team that builds some of the most used blockchain infrastructure and apps. The collaboration gives Fireblocks’ clients the ability to go direct to DeFi and brings advanced DeFi trading features to TradFi. Its key features include: Competitive Pricing and Deep Liquidity: Access to onchain and offchain liquidity. It offers an average price improvement of 4.6 basis points compared to the leading aggregator. Simplified DeFi Trading: Go direct to DeFi with minimal latency and zero hassle. Uniswap’s Trading API handles the complexities of onchain trading including gas estimates, slippage calculations, routing options and USD conversions. Vast Selection Across 12 Chains: Thousands of assets across 12 chains, and growing. Access to Arbitrum, Avalanche, Base, Blast, BNB Chain, Celo, Ethereum, Optimism, Polygon, Unichain, World Chain, Zora, and ZKsync. Bringing DeFi Innovation to TradFi Institutions that choose to go direct to DeFi can also configure the API to their business operations, allowing funds to flow directly to designated wallets for better accounting and transparency. To learn more visit https://hub.uniswap.org About Uniswap Labs: Uniswap Labs is a software company founded in 2018 by Hayden Adams, the company’s CEO, who invented the Uniswap Protocol, a peer-to-peer system for swapping digital assets that has processed $2.4T in volume since its founding. Uniswap Labs builds some of the most widely adopted DeFi products including a self-custody mobile wallet, an API for professional market players and a web interface. About Fireblocks: Fireblocks is an easy-to-use platform to create new blockchain-based products, and manage day-to-day digital asset operations. Exchanges, banks, PSPs, lending desks, custodians, trading desks, and hedge funds can securely scale their digital asset operations through the Fireblocks Network and MPC-based Wallet Infrastructure. Fireblocks serves thousands of organizations in the financial, payments, and web3 space, has secured the transfer of over $6 trillion in digital assets and has a unique insurance policy that covers assets in storage and transit. Find out more at www.fireblocks.com View source version on businesswire.com : https://www.businesswire.com/news/home/20241204889966/en/ Media@uniswap.org KEYWORD: UNITED STATES NORTH AMERICA NEW YORK INDUSTRY KEYWORD: PROFESSIONAL SERVICES DATA MANAGEMENT BLOCKCHAIN TECHNOLOGY CRYPTOCURRENCY ASSET MANAGEMENT DIGITAL CASH MANAGEMENT/DIGITAL ASSETS SOURCE: Uniswap Labs Copyright Business Wire 2024. PUB: 12/04/2024 03:00 PM/DISC: 12/04/2024 03:02 PM http://www.businesswire.com/news/home/20241204889966/enCostco Wholesale Corporation Reports November Sales Results
BOONE, N.C. (AP) — Myles Tate led Appalachian State with 20 points and Dior Conners hit the game-winning 3-pointer with one second left as the Mountaineers defeated William & Mary 79-76 on Sunday. Read this article for free: Already have an account? To continue reading, please subscribe: * BOONE, N.C. (AP) — Myles Tate led Appalachian State with 20 points and Dior Conners hit the game-winning 3-pointer with one second left as the Mountaineers defeated William & Mary 79-76 on Sunday. Read unlimited articles for free today: Already have an account? BOONE, N.C. (AP) — Myles Tate led Appalachian State with 20 points and Dior Conners hit the game-winning 3-pointer with one second left as the Mountaineers defeated William & Mary 79-76 on Sunday. Tate had five rebounds and 10 assists for the Mountaineers (3-2). Conners went 5 of 9 from the field (5 for 8 from 3-point range) to add 15 points. CJ Huntley shot 6 of 9 from the field and 1 for 4 from the line to finish with 14 points. Noah Collier led the Tribe (3-5) in scoring, finishing with 19 points and eight rebounds. William & Mary also got 13 points from Malachi Ndur. Kyle Pulliam also had 12 points. Appalachian State went into the half leading William & Mary 42-30. Jamil Muttilib put up 12 points in the half. Tate led Appalachian State with 15 points in the second half. NEXT UP Appalachian State plays Wednesday against Sam Houston, and William & Mary visits Old Dominion on Monday. ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar. Advertisement
Dec 11 (Reuters) - Morrison Foerster said on Wednesday that it has hired a team of seven lawyers from rival U.S. law firm Goodwin Procter, including partner Peter Fusco, who will co-lead its emerging companies and venture capital group. Joining Fusco as partners at the San Francisco-founded Morrison Foerster are Jae Zhou and Frank Paz. The New York-based lawyers advise venture funds, startups and other early-stage technology companies, which can be an attractive client base for law firms. The group's other co-chairs, Michael Glaser and Jim Krenn, are based in California. Glaser in a statement said Fusco's tech-focused team expands its presence in New York's "dynamic business market." Fusco was not immediately available for comment. Morrison Foerster's website lists more than 100 lawyers in its emerging companies group. The firm has more than 1,000 attorneys globally. At Goodwin, Fusco co-led a team of lawyers that advised Salt Lake City-based Pathology Watch on its sale to Sydney, Australia-based Sonic Healthcare in 2023, according to a Goodwin announcement of its work on the deal. Fusco and other lawyers on the team joined Goodwin as part of a group hire of technology attorneys from Orrick Herrington & Sutcliffe in 2021. Another lawyer from that group, William Wilson, joined Morrison Foerster's technology transactions group from Goodwin in July. In March, Morrison Foerster had hired five cybersecurity lawyers from Goodwin, including a practice leader. A Goodwin spokesperson said the firm wishes Fusco well. Sign up here. Reporting by Sara Merken Our Standards: The Thomson Reuters Trust Principles. , opens new tab Thomson Reuters Sara Merken reports on the business of law, including legal innovation and law firms in New York and nationally.
DORAL, Fla.--(BUSINESS WIRE)--Dec 23, 2024-- NeueHealth, Inc. (“NeueHealth” or the “Company”) (NYSE: NEUE), the value-driven healthcare company, today announced that it has entered into a definitive merger agreement pursuant to which the Company will be acquired by an affiliate of New Enterprise Associates (“NEA”) at an enterprise value of approximately $1.3 billion. Upon completion of the transaction, NeueHealth will become a privately held company with the flexibility and resources to continue advancing its value-driven, consumer-centric care model. Under the terms of the merger agreement, holders of NeueHealth common stock (other than shares that will be rolled over and certain excluded shares) will receive $7.33 per share in cash, which represents a premium of approximately 70% over the closing price of NeueHealth common stock on December 23, 2024. Certain stockholders of NeueHeath, including NEA and 12 existing NeueHealth investors (which collectively hold all of the outstanding shares of NeueHealth preferred stock), have entered into rollover agreements pursuant to which such stockholders will continue their investments by exchanging their shares of NeueHealth common stock and/or preferred stock for newly issued equity interests in the privately held company, and the Company’s existing secured loan facility with Hercules Capital, Inc. will remain in place. NeueHealth’s executive leadership team will continue in their roles upon completion of the transaction and intends to roll over 100% of their equity interests for newly issued equity interests in the privately held company. “We are pleased to announce this transaction as we believe it places NeueHealth in a strong position for continued growth while maximizing value for all of NeueHealth’s public stockholders,” said Mike Mikan, President and CEO of NeueHealth. “NEA has been a longstanding strategic partner, and we look forward to continuing to work together to build on NeueHealth’s success as a leader in value-based care.” “We believe NeueHealth has built a differentiated model of care that is uniquely positioned to drive value for consumers, providers, and payors and we have confidence in the NeueHealth team and their ability to continue to lead the Company,” said Mohamad Makhzoumi, Co-CEO of NEA. “We have had a strong partnership with NeueHealth since 2016 and share the Company’s commitment to making high-quality healthcare accessible and affordable for all Americans.” Transaction Details A special committee (the “Special Committee”) of the board of directors of NeueHealth (the “Board”), composed entirely of independent and disinterested directors and advised by its own independent legal and financial advisors, unanimously recommended that the Board approve the transaction and determined it was in the best interests of the Company and its stockholders that are not affiliated with NEA. Acting upon the recommendation of the Special Committee, the Board subsequently unanimously approved the transaction and determined to recommend that NeueHealth stockholders vote to approve and adopt the merger agreement. Certain NeueHealth stockholders have agreed to vote all of their shares of NeueHealth common stock and/or preferred stock to approve and adopt the merger agreement, subject to certain conditions. The merger is subject to approval by NeueHealth’s stockholders and other customary closing conditions, including receipt of certain regulatory approvals. NEA intends to finance the transaction with fully committed equity financing, and the transaction is not subject to any financing condition. Upon completion of the transaction, NeueHealth’s common stock will no longer be publicly traded or listed on any public market. The merger agreement includes a 30-day “go-shop” period that will expire at 12:01 AM New York City time on January 23, 2025, which permits the Special Committee and its financial advisors to solicit and consider alternative acquisition proposals. There can be no assurance that this process will result in a superior proposal, and NeueHealth does not intend to disclose developments with respect to the “go-shop” process unless and until it determines such disclosure is appropriate or is otherwise required. Lincoln International, LLC is acting as financial advisor, and Richards, Layton & Finger, P.A. is acting as legal counsel, to the Special Committee. Simpson Thacher & Bartlett LLP is acting as legal counsel to NeueHealth. Latham and Watkins LLP is acting as legal counsel to NEA, with Sidley Austin LLP acting as insurance regulatory counsel to NEA. More information regarding the key terms will be included in a current report on Form 8-K to be filed by NeueHealth with the Securities and Exchange Commission (the “SEC”). Important Information and Where to Find It In connection with the transaction, the Company will file with the SEC a proxy statement on Schedule 14A (the “Proxy Statement”), the definitive version of which will be sent or provided to Company stockholders. The Company, affiliates of the Company and affiliates of NEA intend to jointly file a transaction statement on Schedule 13E-3 (the "Schedule 13E-3") with the SEC. The Company may also file other documents with the SEC regarding the transaction. This release is not a substitute for the Proxy Statement, the Schedule 13E-3 or any other document which the Company may file with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT, THE SCHEDULE 13E-3 AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BEFORE MAKING ANY VOTING OR INVESTMENT DECISION WITH RESPECT TO THE COMPANY OR THE TRANSACTION BECAUSE THESE DOCUMENTS CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTION AND RELATED MATTERS. Investors and security holders may obtain free copies of the Proxy Statement, the Schedule 13E-3 and other documents that are filed or will be filed with the SEC by the Company, when such documents become available, through the website maintained by the SEC at www.sec.gov or through the Company's website at https://investors.neuehealth.com/home/default.aspx . The transaction will be implemented solely pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024 (the “merger agreement”), among the Company, NH Holdings 2025, Inc. and NH Holdings Acquisition 2025, Inc., which contains the full terms and conditions of the transaction. Participants in the Solicitation The Company and certain of its directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from stockholders of the Company in connection with the proposed transaction. Information regarding the Company’s directors and executive officers is available in the definitive proxy statement for the 2024 annual meeting of stockholders of the Company, which was filed by the Company with the SEC on April 1, 2024 (the “Annual Meeting Proxy Statement”), and will be available in the Proxy Statement. Please refer to the sections captioned “Executive Compensation,” “Director Compensation,” and “Security Ownership of Certain Beneficial Owners and Management” in the Annual Meeting Proxy Statement. Holdings of the Company’s securities by certain of the Company’s employees, and any changes in the holdings of the Company’s securities by the Company’s directors or executive officers from the amounts described in the Annual Meeting Proxy Statement, have been reflected in the following Statements of Change in Ownership on Form 4 filed with the SEC: Form 4, filed by George Lawrence Mikan III on May 6, 2024; Form 4, filed by Jay Matushak on May 6, 2024; Form 4, filed Tomas Orozco on May 6, 2024; Form 4, filed by Jeffery Michael Craig on May 6, 2024; Form 4, filed by Jeffrey J. Scherman on May 6, 2024; Form 4, filed by Jay Matushak on May 13, 2024; Form 4, filed by Jeffrey J. Scherman on May 13, 2024; Form 4, filed by Kedrick D. Adkins, Jr. on May 14, 2024; Form 4, filed by Andrew M. Slavitt on May 14, 2024; Form 4, filed by Linda Gooden on May 14, 2024; Form 4, filed by Mohamad Makhzoumi on May 14, 2024; Form 4, filed by Robert J. Sheehy on May 14, 2024; Form 4, filed by Matthew G. Manders on May 14, 2024; Form 4, filed by Stephen Kraus on May 14, 2024; Form 4, filed by Manuel Kadre on May 14, 2024; Form 4, filed by Jeffrey R. Immelt on May 14, 2024; Form 4, filed by Mohamad Makhzoumi on October 3, 2024; Form 4, filed by Jay Matushak on October 8, 2024; Form 4, filed by George Lawrence Mikan III on December 18, 2024. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Proxy Statement and other relevant materials to be filed with the SEC in connection with the proposed transaction when they become available. Free copies of the Proxy Statement and such other materials may be obtained as described in the preceding paragraph. About NeueHealth NeueHealth is a value-driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated care. By uniquely aligning the interests of health consumers, providers, and payors, NeueHealth helps to make healthcare accessible and affordable to all populations across the ACA Marketplace, Medicare, and Medicaid. NeueHealth delivers high-quality clinical care to over 500,000 health consumers through owned clinics and unique partnerships with over 3,000 affiliated providers. We also enable independent providers and medical groups to thrive in performance-based arrangements through a suite of technology and services scaled centrally and deployed locally. We believe our value-driven, consumer-centric care model can transform the healthcare experience and maximize value across the healthcare system. For more information, visit: www.neuehealth.com . About NEA New Enterprise Associates (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. Founded in 1977, NEA has more than $25 billion in assets under management as of June 30, 2024 and invests in technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm's long track record of investing includes more than 280 portfolio company IPOs and more than 465 mergers and acquisitions. For more information, please visit www.nea.com . Forward-Looking Statements This release contains certain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements made in this release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies, and statements as to the expected timing, completion and effects of the transaction. These statements often include words such as “anticipate,” “expect,” “plan,” “believe,” “intend,” “project,” “forecast,” “estimates,” “projections,” “outlook,” “ensure,” and other similar expressions. These forward-looking statements include any statements regarding our plans, expectations and financial guidance. Such forward-looking statements are subject to various risks, uncertainties and assumptions. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Factors that might materially affect such forward-looking statements include: the failure to complete the transaction on the anticipated terms and within the anticipated timeframe, including as a result of failure to obtain required stockholder or regulatory approvals or to satisfy other closing conditions; potential litigation relating to the transaction that could be instituted against NEA, the Company or their respective affiliates, directors, managers, officers or employees, and the effects of any outcomes related thereto; potential adverse reactions or changes to our business relationships or operating results resulting from the announcement, pendency or completion of the transaction; the risk that our stock price may decline significantly if the transaction is not consummated; certain restrictions during the pendency of the transaction that may impact our ability to pursue certain business opportunities or strategic transactions; costs associated with the transaction, which may be significant; the occurrence of events, changes or other circumstances that could give rise to the termination of the merger agreement, including in circumstances requiring us to pay a termination fee; our ability to continue as a going concern; our ability to comply with the terms of our credit facilities or any credit facility into which we enter in the future; our ability to receive the remaining proceeds from the sale of our Medicare Advantage business in California in a timely manner; our ability to obtain any short or long term debt or equity financing needed to operate our business; our ability to quickly and efficiently complete the wind down of our remaining Individual and Family Plan (“IFP”) and MA businesses, including by satisfying liabilities of those businesses when due and payable; potential disruptions to our business due to the transaction or due to corporate restructuring and any resulting headcount reduction; our ability to accurately estimate and effectively manage the costs relating to changes in our business offerings and models; a delay or inability to withdraw regulated capital from our subsidiaries; a lack of acceptance or slow adoption of our business model; our ability to retain existing consumers and expand consumer enrollment; our and our care partner’s abilities to obtain and accurately assess, code, and report risk adjustment factor scores; our ability to contract with care providers and arrange for the provision of quality care; our ability to obtain claims information timely and accurately; the impact of any pandemic or epidemic on our business and results of operations; the risks associated with our reliance on third-party providers to operate our business; the impact of modifications or changes to the U.S. health insurance markets; our ability to manage any growth of our business; our ability to operate, update or implement our technology platform and other information technology systems; our ability to retain key executives; our ability to successfully pursue acquisitions, integrate acquired businesses, and quickly and efficiently divest businesses as needed; the occurrence of severe weather events, catastrophic health events, natural or man-made disasters, and social and political conditions or civil unrest; our ability to prevent and contain data security incidents and the impact of data security incidents on our members, patients, employees and financial results; our ability to comply with requirements to maintain effective internal controls; our ability to adapt to mitigate risks associated with our ACO businesses, including any unanticipated market or regulatory developments; and the other factors set forth under the heading “Risk Factors” in the Company’s reports on Form 10-K, Form 10-Q, and Form 8-K (including all amendments to those reports) and our other filings with the SEC. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this release to conform these statements to actual results or changes in our expectations. View source version on businesswire.com : https://www.businesswire.com/news/home/20241223595862/en/ CONTACT: Investor Contact: IR@neuehealth.comMedia Contact: media@neuehealth.com KEYWORD: FLORIDA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: PRACTICE MANAGEMENT PROFESSIONAL SERVICES MANAGED CARE HEALTH GENERAL HEALTH HEALTH TECHNOLOGY HEALTH INSURANCE HOSPITALS INSURANCE TELEMEDICINE/VIRTUAL MEDICINE FINANCE SOURCE: NeueHealth Copyright Business Wire 2024. PUB: 12/23/2024 05:53 PM/DISC: 12/23/2024 05:53 PM http://www.businesswire.com/news/home/20241223595862/enFive things to know about Panama Canal, in Trump's sightsDonald Trump will ring the New York Stock Exchange bell as he's named Time's Person of the Year
COP29: Developing nations slam 'paltry' $300 billion climate dealThe Long Game: John McEntee on his vision for shaping the conservative movement over the next decade
Jacob Bethell to make England Test debut at number three against New ZealandWARREN, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") TVGN , a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today expresses gratitude to shareholders for their unwavering support and trust in Tevogen Bio and its leadership. The commitment fuels the company's determination to advance its mission of developing accessible, life-saving therapeutics. The company recently announced significant progress through its third quarter financial results for 2024, including, reduction of a net loss by $52.5 million, elimination of nearly all liabilities, and reiterating availability of sufficient capital to fund operations for the next 33 months. Ryan Saadi, MD, MPH, Founder and CEO, Tevogen Bio commented, "We remain steadfast in our mission to advance medical science, however as CEO of the company, preservation of shareholder value remains a priority. We urge all stakeholders to consider the profound impact short selling innovative healthcare companies has on lifesaving therapies. While stock price fluctuations are part of the public market dynamics, Tevogen Bio is acutely aware of the undue influence short sellers have." William Keane, VP of Strategic Initiatives, and graduate of the FBI National Academy stated, "We are aware and monitoring the actions of potential short selling activity targeting our company. We will continue to bring light to this situation and will work with the appropriate authorities as needed." The company plans to provide further updates on its progress in the coming weeks. About Tevogen Bio Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation. Forward-Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases, cancer and neurological disorders, including TVGN 489 for the treatment of COVID-19 and Long COVID; Tevogen's ability to develop additional product candidates, including through use of Tevogen's ExacTcell platform; the anticipated benefits of ExacTcell; expectations regarding Tevogen's future clinical trials; and Tevogen's ability to generate revenue in the future. Forward-looking statements can sometimes be identified by words such as "may," "could," "would," "expect," "anticipate," "possible," "potential," "goal," "opportunity," "project," "believe," "future," and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the "Business Combination") on Tevogen's business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law. Contacts Tevogen Bio Communications T: 1 877 TEVOGEN, Ext 701 Communications@Tevogen.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.OVIEDO, Spain One man died on Sunday and another was injured while inspecting a school damaged by recent catastrophic flooding in Valencia. Nearly a month ago, record-breaking rains in the area caused extreme flash flooding and killed at least 229 people, according to the latest government figures. The rivers that ripped through the streets of several towns also caused billions of dollars worth of damage to buildings, infrastructure and businesses. Many parts of the affected area are still damaged and covered in mud. The school in the town of Massanassa was one of the thousands of badly damaged buildings. As two workers were inspecting the school, which has been shut down since the deadly disaster, part of the roof collapsed, killing a 51-year-old man and injuring a 35-year-old. “I would like to thank and acknowledge the work of all those who are tirelessly engaged in the recovery efforts,” Spanish Prime Minister Pedro Sanchez posted on X, sending his condolences to the victim’s loved ones. “This type of accident cannot happen again,” Valencian President Carlos Mazon wrote on X. Sunday’s victims were working for a public company in the region’s gargantuan cleanup efforts. Besides local workers, firefighters and volunteers, nearly 8,500 military officers and 9,750 national police officers have been deployed to help restore normalcy to the devastated area. Nearly one month after the floods, at least 16,000 children affected by the floods have not returned to school, according to El Pais daily. Similarly, only 365 social housing units are available in the area despite 2,147 homes having been rendered uninhabitable. El Pais said although the situation in flood-struck areas has improved in recent weeks, the lives of residents, basic services and business activity are still far from normal. So far, the Spanish government has announced €14.4 billion ($15 billion) in financial aid to help affected households and businesses. The premier has called this the worst natural disaster in the country's modern history. Meanwhile, five people remain missing, and search efforts continue to locate their bodies.
Bernard Looney Appointed Chairman of the Board of Directors at Prometheus Hyperscale
Apple's latest iPhones get the gift of more AI as holiday shopping season heats upLiverpool midfielder Alexis Mac Allister has been ruled out of Saturday's Merseyside derby against Everton through suspension. The Argentina international made his 12th Premier League start of the season in Wednesday's Premier League away clash against Newcastle. Liverpool fought back on two occasions to restore parity before Mohamed Salah scored his second goal of the game to give the Reds a 3-2 lead. However, Arne Slot 's side were ultimately left frustrated after Fabian Schar netted a 90th-minute equaliser to deny Liverpool an eighth consecutive win in all competitions. The Liverpool boss would have also been disappointed to see Mac Allister pick up a costly yellow card in the first half at St James' Park. Mac Allister had been at risk of suspension since he picked up his fourth yellow card of the Premier League season in a 2-1 win over Brighton & Hove Albion on November 2. Unfortunately for Liverpool, Mac Allister was shown a yellow card in the 20th minute against Newcastle following a foul on Schar. After collecting his fifth league booking, the World Cup winner will serve a one-match suspension, ruling him out of the first Merseyside derby of the season. Mac Allister will sit out Saturday's trip to Goodison Park alongside the injured Alisson Becker , Conor Bradley , Ibrahima Konate and Kostas Tsimikas . There are also question marks surrounding the availability of Diogo Jota and Federico Chiesa , who will have to be assessed ahead of the derby clash. With Mac Allister suspended, Slot will have to decide which player will replace the 25-year-old in the Liverpool engine room. Curtis Jones may drop into a deeper role alongside Ryan Gravenberch , allowing Dominik Szoboszlai to come into the side to operate as an attacking midfielder. While that seems like the most realistic solution, Slot has the option to start Wataru Endo or Tyler Morton and allow Jones to stay in his advanced position. Having avoided defeat in their last 10 league games, Liverpool will head into the derby as the Premier League leaders , with a seven-point advantage at the top of the table.
Grand Tamasha: Decoding India’s policies, their impact in near EastNEW YORK--(BUSINESS WIRE)--Dec 4, 2024-- Figure Technology Solutions (“Figure”), a technology platform powering a more efficient and liquid marketplace for financial products, today announced that Macrina Kgil, a seasoned finance executive, joined as Chief Financial Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204327766/en/ (Photo: Business Wire) “Macrina is the perfect fit for Figure, given her industry expertise and deep background in public markets and public company finance functions,” said Michael Tannenbaum, Chief Executive Officer of Figure. He continued, “We recently surpassed $1.5 billion in quarterly originations, record revenue, eighty percent year over year growth, and one hundred fifty percent EBITDA growth. Our metrics reflect three primary drivers: the widespread adoption of our increasingly liquid lending marketplace, Figure Connect, coupled with both a diversified product suite and a growing network of embedded lending partners. Our steady growth and ambitious plans called for a CFO of Macrina’s caliber; her financial stewardship will be pivotal to helping Figure achieve our goals.” “I’m thrilled to join Figure and have the opportunity to work alongside a deep executive bench and lead a talented finance team,” said Kgil. ‘’Particularly given my extensive experience in the fintech and blockchain sectors, I am eager to drive our growth and nurture investor confidence. Figure operates at the forefront of innovation, and I believe that we can unlock significant value for all of our stakeholders as we continue our momentum.” Kgil joins Figure from Flow, a residential real estate startup, where she led the finance function globally. Prior to Flow, Kgil was CFO of OneMain Holdings (NYSE: OMF). While there, she helped manage the acquisition of OneMain Holdings from Citigroup, and successfully led the company (as Springleaf Finance) through an IPO, managing the public markets debut as well as subsequently guiding the company as a public filer. Previously, she served as CFO of Blockchain.com and its affiliate Blockchain Ventures Fund I, where she built a robust finance infrastructure across numerous global entities with a strong regulatory and compliance focus. Earlier, she served as VP in the private equity group at Fortress Investment Group and started her career at PwC in the capital market advisory and audit teams. Kgil holds an engineering degree from Seoul National University. She’s a founding member of the F Suite, an executive community of leading CFOs. Kgil reports to Tannenbaum in this newly created role for Figure, following its spin-off earlier this year as a stand-alone company independent of Figure Markets Holdings. Her hiring follows September’s appointment of Ron Chillemi as Figure’s first Chief Legal Officer. About Figure Technology Solutions Founded in 2018, Figure Technology Solutions (“Figure”) is a disruptive and scaled technology platform built to enhance efficiency and transparency in financial services. Its subsidiary, Figure Lending LLC, is the largest non-bank provider of home equity lines of credit; its software has been used to originate more than $12B of home equity lines of credit. Figure’s technology is embedded across a broad network of loan originators and capital markets buyers, and is used directly as well by homeowners in 49 states and Washington, DC. With Figure, homeowners can receive approval for a HELOC in as fast as five minutes and receive funding in as few as five days. To date, Figure has embedded its HELOC in more than 135 partners, including Rate (formerly Guaranteed Rate), CrossCountry Mortgage, Movement Mortgage, Goodleap and many other fintechs, depositories and independent mortgage banks. View source version on businesswire.com : https://www.businesswire.com/news/home/20241204327766/en/ press@figure.com KEYWORD: UNITED STATES NORTH AMERICA NEW YORK INDUSTRY KEYWORD: COMMERCIAL BUILDING & REAL ESTATE CONSTRUCTION & PROPERTY FINANCE CONSULTING BANKING PROFESSIONAL SERVICES FINTECH RESIDENTIAL BUILDING & REAL ESTATE SOURCE: Figure Technology Solutions Copyright Business Wire 2024. PUB: 12/04/2024 03:00 PM/DISC: 12/04/2024 03:02 PM http://www.businesswire.com/news/home/20241204327766/en
- Previous:
- Next: is sports betting legal in florida
